You are here: Welcome to the MPKB » Welcome to the MPKB » Resources for physicians » Physicians' concerns about the Marshall Protocol
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revisionBoth sides next revision
home:physicians:concerns [02.09.2019] – [Concerns about lack of clinical evidence] sallieqhome:physicians:concerns [02.09.2019] – [Concerns about lack of clinical evidence] sallieq
Line 16: Line 16:
 For some physicians, the above evidence is not sufficiently compelling to warrant automatically starting a patient on the MP without further consideration. Here are some other factors which may play a role in the clinical judgment: For some physicians, the above evidence is not sufficiently compelling to warrant automatically starting a patient on the MP without further consideration. Here are some other factors which may play a role in the clinical judgment:
   * evidence for the efficacy of MP versus other available treatment options(({{pubmed>long:19050187}}))   * evidence for the efficacy of MP versus other available treatment options(({{pubmed>long:19050187}}))
-  * patients' expressed preferences and values(({{pubmed>long:19050187}})) 
   * more recent material on patient response, see below update   * more recent material on patient response, see below update
 +  * patients' expressed preferences and values(({{pubmed>long:19050187}}))
   * additional benefits of Olmesartan [[https://mpkb.org/home/protocol/olmesartan#other_benefits_of_olmesartan_in_patients_-_recent_studies|other researched benefits]]   * additional benefits of Olmesartan [[https://mpkb.org/home/protocol/olmesartan#other_benefits_of_olmesartan_in_patients_-_recent_studies|other researched benefits]]
   * orphan drug status – Autoimmunity Research Foundation has won [[home:publications:applications_orphan_status|orphan drug status]] from the FDA for several medications and indications, and is committed to working further with the agency to get the MP approved for a broader range of indications.   * orphan drug status – Autoimmunity Research Foundation has won [[home:publications:applications_orphan_status|orphan drug status]] from the FDA for several medications and indications, and is committed to working further with the agency to get the MP approved for a broader range of indications.
home/physicians/concerns.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.